Vascular Biogenics Ltd. (NASDAQ:VBLT) is reporting third quarter financial results on Monday 16th November 2020, before market open.
According to analysts surveyed by Thomson Reuters, VBLT is expected to report 3Q20 loss of $ 0.13 per share from revenue of $ 0.17 million.
For the full year, analysts anticipate top line of $ 0.80 million, while looking forward to loss of $ 0.55 per share bottom line.
Previous Quarter Performance
Vascular Biogenics Ltd. outlined loss for the second quarter of $ 0.14 per share, from the revenue of $ 0.16 million. Wall street analysts are predicting, VBLT to report 2Q20 loss of $ 0.14 per share from revenue of $ 0.15 million. The top line results outshined analysts by $ 0.01 million or 6.67 percent.
Stock Performance
On Friday, shares of Vascular Biogenics Ltd. has traded high as $ 1.18 and has cracked $ 1.12 on the downward trend, reaching $ 1.18 with volume of 115.80 thousand shares.
According to the previous trading day, closing price of $ 1.18, representing a 23.33 % increase from the 52 week low of $ 0.90 and a 32.32 % decrease over the 52 week high of $ 1.64.
The company has a market capital of $ 56.52 million and is part of the Healthcare sector and Biotechnology industry.
Conference Call
Vascular Biogenics Ltd. will be hosting a conference call at 8:30 AM eastern time on 16th November 2020, to discuss its 3Q20 financial results with the investment community. The participants may dial, 877-407-9208 or 201-493-6784 Toll Number, when prompted, enter passcode 13711944 in order to access the live audio call. A live webcast with presentations will be available on the Internet by visiting the Company website www.vblrx.com
Vascular Biogenics Ltd., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of treatments for cancer. The companys program is based on its proprietary vascular targeting system platform technology, which utilizes genetically targeted therapy to destroy newly formed or angiogenic blood vessels. Its lead product candidate is VB-111, a gene-based biologic that is in Phase III clinical trials for the treatment of recurrent glioblastoma, an aggressive form of brain cancer; and in Phase III clinical trials for recurrent platinum-resistant ovarian cancer, as well as for Phase II clinical trials for iodine-resistant differentiated thyroid cancer.
